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Abstract 
Background: Strategies to maintain BBB integrity in diseases with a hypoxia/reoxygenation (H/R) component involve 
preventing glutathione (GSH) loss from endothelial cells. GSH efflux transporters include multidrug resistance proteins 
(Mrps). Therefore, characterization of Mrp regulation at the BBB during H/R is required to advance these transporters 
as therapeutic targets. Our goal was to investigate, in vivo, regulation of Abcc1, Abcc2, and Abcc4 mRNA expression 
(i.e., genes encoding Mrp isoforms that transport GSH) by nuclear factor E2-related factor (Nrf2) using a well-estab-
lished H/R model.
Methods: Female Sprague–Dawley rats (200–250 g) were subjected to normoxia (Nx, 21% O2, 60 min), hypoxia (Hx, 
6% O2, 60 min) or H/R (6% O2, 60 min followed by 21% O2, 10 min, 30 min, or 1 h) or were treated with the Nrf2 activa-
tor sulforaphane (25 mg/kg, i.p.) for 3 h. Abcc mRNA expression in brain microvessels was determined using quantita-
tive real-time PCR. Nrf2 signaling activation was examined using an electrophoretic mobility shift assay (EMSA) and 
chromatin immunoprecipitation (ChIP) respectively. Data were expressed as mean ± SD and analyzed via ANOVA 
followed by the post hoc Bonferroni t test.
Results: We observed increased microvascular expression of Abcc1, Abcc2, and Abcc4 mRNA following H/R treatment 
with reoxygenation times of 10 min, 30 min, and 1 h and in animals treated with sulforaphane. Using a biotinylated 
Nrf2 probe, we observed an upward band shift in brain microvessels isolated from H/R animals or animals adminis-
tered sulforaphane. ChIP studies showed increased Nrf2 binding to antioxidant response elements on Abcc1, Abcc2, 
and Abcc4 promoters following H/R or sulforaphane treatment, suggesting a role for Nrf2 signaling in Abcc gene 
regulation.
Conclusions: Our data show increased Abcc1, Abcc2, and Abcc4 mRNA expression at the BBB in response to H/R 
stress and that Abcc gene expression is regulated by Nrf2 signaling. Since these Mrp isoforms transport GSH, these 
results may point to endogenous transporters that can be targeted for BBB protection during H/R stress. Experiments 
are ongoing to examine functional implications of Nrf2-mediated increases in Abcc transcript expression. Such studies 
will determine utility of targeting Mrp isoforms for BBB protection in diseases with an H/R component.
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Background
Cerebral hypoxia and reoxygenation (H/R) is a compo-
nent of various diseases including traumatic brain injury, 
cardiac arrest, and ischemic stroke [1]. Blood–brain bar-
rier (BBB) integrity is modulated by production of reac-
tive oxygen species (ROS) and subsequent oxidative 
stress in the setting of H/R [2]. For example, studies using 
bovine brain microvessel endothelial cells subjected to 
H/R stress reported discrete changes in tight junction 
protein localization that correlated with increased para-
cellular permeability to sucrose, a vascular marker that 
does not cross the intact BBB [3]. Similar observations 
have been reported in  vivo where H/R induced disas-
sembly of occludin oligomers in rat brain microvessels 
[4, 5]. Furthermore, studies in the same model system 
showed increased CNS accumulation of sucrose [5, 6] 
and dextrans [7], evidence indicating BBB dysfunction 
in response to H/R. Indeed, vascular changes induced 
by H/R can have deleterious consequences. Enhanced 
BBB permeabilization can lead to vasogenic edema and 
cause clinically significant increases in brain volume and 
intracranial pressure [8, 9]. Additionally, substances that 
are typically contained within the systemic circulation, 
including drugs, can leak into brain parenchyma and 
potentially cause neurotoxicity. Clearly, there is a critical 
need to preserve BBB integrity in diseases with an H/R 
component.
In order to develop therapeutic approaches that can 
confer BBB protection, it is essential to identify specific 
biological mechanisms that contribute to oxidative stress-
induced damage of the brain microvasculature. Indeed, 
furthering our understanding of the endothelial cell anti-
oxidant defense system will enable advancement of such 
pharmacological strategies. The endogenous antioxidant 
glutathione (GSH) is a vital component of this antioxi-
dant defense system. In  vivo studies have demonstrated 
that cerebral GSH levels are significantly decreased in 
response to reperfusion injury [10] and GSH depletion 
is associated with increased BBB permeability to both 
sucrose and sodium fluorescein [11]. Although this does 
not reflect large-scale BBB disruption, this leak is clini-
cally significant by permitting increased paracellular 
transport of potentially toxic small molecules. Decreased 
GSH levels in response to H/R may involve membrane 
transport processes mediated by multidrug resistance 
proteins (Mrps). Mrps are members of the ATP-binding 
cassette (ABC) superfamily of efflux transporters, pri-
marily transport organic anions and conjugated metabo-
lites, and are encoded by genes from ABC subfamily C 
(i.e., Abcc genes) [2]. Both GSH and glutathione disulfide 
(GSSG) are known transport substrates for Mrp1, Mrp2, 
and Mrp4. For example, studies in primary cultures of rat 
astrocytes showed that GSH transport could be blocked 
using MK571, an established inhibitor of Mrp1 and Mrp2 
[12–14]. Similarly, Mrp4 is also believed to be involved in 
transport of GSH in the brain [15]. Indeed, these obser-
vations point towards endogenous transporters that can 
be targeted to preserve endothelial GSH levels and pro-
vide BBB protection in the setting of H/R.
Effective targeting of Mrps to reduce GSH efflux and 
confer BBB protection requires identification and char-
acterization of regulatory pathways that control expres-
sion of these transporters. One such pathway is signaling 
mediated by nuclear factor E2-related factor (Nrf2). Nrf2 
is normally inactive in the cytoplasm and rapidly 
degraded when associated with Kelch-like ECH-asso-
ciated protein 1 (Keap1). Under conditions of oxidative 
stress, Keap1 dissociates and allows Nrf2 to translocate 
to the nucleus and initiate transcription of genes contain-
ing an antioxidant response element (ARE) [16]. Nrf2 
has been shown to induce expression of Mrp1, Mrp2, 
and Mrp4 and the genes that encodes these proteins (i.e., 
Abcc1, Abcc2, Abcc4) at the BBB as well as in other tis-
sues [17–19]. At present, involvement of Nrf2 in regulat-
ing Mrp transporter expression at the BBB has not been 
evaluated under pathophysiological conditions.
In the present study, we show increased expression 
of Abcc1, Abcc2, and Abcc4 mRNA transcripts in brain 
microvessels via Nrf2 signaling in the setting of H/R. Spe-
cifically, we show for the first time that H/R activates Nrf2 
signaling at the BBB and that Nrf2 binds to an antioxi-
dant response element in the promoter of all three genes 
that encode GSH transporting Mrp isoforms. These data 
provide critical information that can inform future stud-
ies aimed at targeting Mrp transporters to confer BBB 
protection in diseases with an H/R component.
Methods
Animals and treatments
All animal experiments were approved by the University 
of Arizona Institutional Animal Care and Use Commit-
tee and conform to National Institutes of Health guide-
lines. Female Sprague–Dawley rats (200–250  g) were 
obtained from Envigo (Denver, CO), housed under stand-
ard 12  h light/12  h dark conditions, and provided with 
food and water ad libitum. Female rats were purposely 
selected for this study in order to correlate our results 
with previous data on BBB transporter changes in the 
setting of H/R [20]. Animals were randomly assigned to 
treatment groups. Animals were subjected to hypoxic 
(Hx) insult (i.e., 6% O2) for 1  h as previously described 
[20]. Using blood-gas analysis, our laboratory has previ-
ously demonstrated that these conditions yield a severe, 
but recoverable, hypoxic insult [20]. Additionally, this 
model increases CNS expression of apoptotic markers 
[i.e., ratio of cleaved poly-ADP ribose polymerase (PARP) 
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to uncleaved PARP] [20]. Rats were then euthanized or 
subjected to reoxygenation (i.e., 21% O2) for 10  min, 
30  min, or 1  h. These time points were selected based 
upon our previous work examining BBB transport mech-
anisms in the setting of H/R [20]. As shown in Thomp-
son et al. [20], discrete changes in BBB transporters can 
be observed during reoxygenation as early as 10  min 
following hypoxic insult. H/R animals were compared 
with animals subjected to Hx only and with normoxic 
(Nx) controls. A subset of animals was administered sul-
foraphane [25 mg/kg (1.0 ml/kg), i.p.; Sigma-Aldrich, St. 
Louis, MO], an established Nrf2 activator, dissolved in 
0.9% saline as a positive control. Following Nx, Hx, H/R 
or 3 h sulforaphane treatment, animals were euthanized 
by decapitation and prepared for microvessel isolation.
Microvessel isolation
Brain microvessels were harvested as previously 
described by our laboratory [20]. Following anesthe-
sia with sodium pentobarbital [64.8  mg/ml (1.0  ml/kg) 
i.p.], rats were decapitated and brains were removed. 
Meninges and choroid plexus were excised and cerebral 
hemispheres were homogenized in 4  ml of microves-
sel isolation buffer (103 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM HEPES, 
pH 7.4) containing protease inhibitor cocktail (Sigma-
Aldrich). After homogenization, 8  ml of 26% dextran 
at 4  °C was added and homogenates were vortexed. 
Homogenates were then centrifuged (5600g; 4  °C) for 
10  min and the supernatant was aspirated. Pellets were 
resuspended in 10  ml of microvessel isolation buffer 
and passed through a 70  μm filter (Becton–Dickinson, 
Franklin Lakes, NJ). Filtered homogenates were pelleted 
by centrifugation at 3000×g for 10  min. At this time, 
the supernatant was aspirated and the pellet, which is 
enriched in brain microvessels, was collected for use in 
further experiments.
Quantitative real‑time PCR analysis
Total RNA was extracted from brain microvessels iso-
lated from rats subjected to Nx, Hx, and H/R using the 
Aurum Total RNA extraction kit (Bio-Rad, Hercules, 
CA). Extracted RNA was treated with amplification grade 
DNase I (Bio-Rad) to remove contaminating genomic 
DNA. The concentration of RNA in each sample was 
quantified spectrophotometrically by measuring UV 
absorbance at 260 nm. The iScript reverse transcriptase 
kit (Bio-Rad) was used to synthesize first-strand cDNA. 
Primer pairs were prepared by Integrated DNA Tech-
nologies (Coralville, IA) with sequences listed in Table 1. 
Each set of primers was designed with the use of Primer 
Express 3 software (Applied Biosystems) and validated 
for specificity and efficacy by using BioTaq universal 
rat normal tissue cDNA (BioTaq Inc., Gaithersburg, 
MD). Primer pairs were designed to be complementary 
to sequences located on two different exons separated 
by an intron in order to avoid amplification of genomic 
DNA. Quantitative PCR was performed using SYBR 
Green Master Mix (Bio-Rad) on a CFX96 Touch Real-
Time PCR Detection System (Bio-Rad). The quantity of 
the target gene (i.e., Abcc1, Abcc2, Abcc4) was normalized 
to GAPDH using the comparative CT method (ΔΔCT). 
Results were expressed as mean  ±  SD of at least three 
separate experiments.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using the LightShift Chemilumi-
nescent EMSA kit (Pierce Biotechnology, Rockford, IL, 
USA) according to manufacturer’s instructions. Briefly, 
nuclear protein extract was isolated from brain microves-
sels prepared from Nx, Hx, H/R, and sulforaphane 
treated rats. Complementary DNA oligonucleotides 
5′-CGG TCA CCG TTA CTC AGC ACT TTG-3′ and 
5′-CAA AGT GCT GAG TAA CGG TGA CCG-3′ 
(antioxidant response element recognition sequence 
highlighted) were purchased from Integrated DNA Tech-
nologies, end labeled with biotin, and annealed at 95  °C 
for 5  min. EMSA samples were prepared using 5  μg of 
nuclear extract in each Nrf2/ARE binding reaction. The 
binding reaction was incubated at room temperature for 
15 min and DNA–protein complexes were resolved on a 
precast 6% native polyacrylamide gel in 0.5% TBE buffer. 
The gel was removed from the electrophoresis unit, blot-
ted onto a nitrocellulose membrane, and incubated with 
Table 1 Quantitative real-time PCR primer sequences
PCR primer sequences
Gene Forward primer Reverse primer
Abcc1 (rat) 5′-TGC-CAG-AGA-TCA-GTT-CAC-ACC-AAG-CC-3′ 5′-ACC-ATC-CGG-ACG-CAG-TTT-GAA-GAC-AG-3′
Abcc2 (rat) 5′-GAA-GGC-ATT-GAC-CCT-ATC-T-3′ 5′-CCA-CTG-AGA-ATC-TCA-TTC-ATG-3′
Abcc4 (rat) 5′-TGG-AAC-TTC-TGG-AGG-ACG-GGG-ATC-TG-3′ 5′-CCC-CTT-CTG-CAC-CAT-TTC-CGG-ATC-TT-3′
GAPDH (rat) 5′-ATG-GCT-ACA-GCA-ACA-GGG-TGG–TGG-AC-3′ 5′-ATG-GGG-TCT-GGG-ATG-GAA-TTG-TGA-GG-3′
Page 4 of 10Ibbotson et al. Fluids Barriers CNS  (2017) 14:6 
streptavidin-horseradish peroxidase for 30  min. Mem-
branes were developed using enhanced chemilumines-
cence. Experiments to determine specificity of EMSA 
reactions for the Nrf2/ARE complex were conducted by 
incubating binding reactions in the presence of a rabbit 
monoclonal anti-Nrf2 antibody (EP1808Y; 1/20 dilution; 
Abcam, Cambridge, MA). Control EMSA experiments 
were performed by adding an excess (200×) of unlabeled 
probe to binding reactions.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the Imprint Chromatin 
Immunoprecipitation Kit (Sigma-Aldrich) according to 
manufacturer’s instructions. Briefly, microvessels were 
isolated from Nx, Hx, H/R, and sulforaphane treated rats 
and subsequently cross-linked in buffer containing 1% 
formaldehyde for 10  min at room temperature. Cross-
linking was stopped by addition of glycine to a final 
concentration of 125  mM followed by centrifugation at 
180×g for 5 min at room temperature. At this time, the 
microvessel pellet was resuspended in 50  μl of Nuclei 
Preparation Buffer and incubated on ice for 10 min. Fol-
lowing centrifugation at 180×g for 10  min at 4  °C, the 
nuclear pellet was resuspended in shearing buffer and 
incubated on ice for 10 min. Chromatin was sheared to 
200–1000 bp by sonication on ice. Sonicated chromatin 
was diluted twofold in lysis buffer and 100 μl of diluted 
sample per immunoprecipitation reaction was used. Each 
sample was added to individual wells of a 96-well assay 
plate where each well contained 1  μg of specific rabbit 
monoclonal anti-Nrf2 antibody (EP1808Y) that has been 
previously validated in ChIP assays [21]. Assay plates 
were incubated for 90  min at room temperature on an 
orbital shaker at 75 rpm. In parallel, a no-antibody sam-
ple was run as a negative control. At this time, 40 μl of 
DNA release buffer was added to each well and samples 
were incubated in a water bath at 65 °C for 15 min. Fol-
lowing this step, 40 μl of reversing solution was added to 
each well and samples were incubated in a water bath at 
65  °C for 90  min. Washes and elutions were performed 
in accordance with manufacturer’s instructions for the 
Imprint ChIP assay kit. Eluted and input DNA samples 
were purified using a spin column to a final volume of 
50  μl. Quantitative real-time PCR was performed using 
2 μl of template DNA per 25 μl of polymerase chain reac-
tion (PCR) amplification scale as described by Hoque and 
colleagues [22]. Quantification of Nrf2 occupancy to the 
ARE within Abcc gene promoter by SYBR green real-time 
PCR was performed using primer sets prepared by Inte-
grated DNA Technologies (Table  2). All measurements 
were performed in triplicate and results were verified in 
three separate chromatin preparations.
Statistical analysis
Data are reported as mean ± SD from at least three sepa-
rate experiments where each treatment group consists 
of pooled microvessels from three individual animals 
(n  =  3). This sample size is based upon the ability to 
detect a 35% difference between treatment groups with 
20% variability. To determine statistical significance, a 
repeated measures ANOVA and post hoc multiple-com-
parison Bonferroni t test were used. A value of p < 0.05 
was accepted as statistically significant.
Results
H/R increases expression of Abcc mRNA transcripts
In order to evaluate and quantitate mRNA expression 
of Abcc mRNA transcripts at the BBB in the setting of 
H/R, we performed quantitative PCR. After completion 
of these experiments, we observed increased expression 
of Abcc1, Abcc2, and Abcc4 mRNA in rat brain microves-
sels following H/R treatment with reoxygenation times of 
10 min, 30 min, and 1 h as compared to Nx controls or 
animals subjected to Hx insult only (Fig. 1). Expression of 
mRNA for all three genes was also increased in animals 
treated with the Nrf2 activator sulforaphane (25  mg/kg 
i.p.) for 3 h (Fig. 1). These studies demonstrate that H/R 
can increase expression of Abcc mRNA at the BBB.
H/R induces nuclear translocation of Nrf2 in rat brain 
microvessels
Since our qPCR data showed increased expression of 
Abcc genes at the BBB in response to H/R, we sought to 
identify a discrete molecular mechanism that is involved 
in induced expression of Abcc mRNA transcripts. We 
postulated that the Nrf2 pathway is one such mecha-
nism. Therefore, we utilized an EMSA with a biotinylated 
probe containing the Nrf2 consensus binding sequence 
Table 2 ChIP primer sequences
Primer sequences for ChIP
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to demonstrate activation of Nrf2 signaling in rat brain 
microvessels following H/R. We observed a shift of the 
probe band to a higher molecular weight and an increase 
in intensity of the probe band in microvessels isolated 
from H/R animals or administered sulforaphane (25 mg/
kg i.p.) for 3 h (Fig. 2). This shift was not observed when 
200-fold excess unlabeled probe was added to EMSA 
reactions (Fig.  2). Incubation of EMSA reactions in the 
presence of the specific rabbit anti-Nrf2 monoclonal 
antibody EP1808Y caused an increase in the shift of the 
probe band, an observation that further indicates nuclear 
translation of Nrf2 under H/R conditions (Fig. 3). Taken 
together, these data provide evidence that H/R can acti-
vate Nrf2 signaling in brain microvessels. 
Nrf2 is involved in regulation of Abcc mRNA transcripts 
in rat brain microvessels following H/R
Since our EMSA experiments demonstrated increased 
Nrf2 nuclear translocation in rat brain microvessels fol-
lowing H/R, we hypothesized that this pathway may be 
involved in transcriptional regulation of Abcc genes. To 
test this hypothesis, we used ChIP to study Nrf2 recruit-
ment to promoter regions on Abcc genes that contain 
the Nrf2 consensus binding sequence [i.e., (a/g)TGA(C/
T/G)nnnGC(a/g)] within the ARE. In H/R animals or in 
animals administered the Nrf2 activator sulforaphane, 
increased Nrf2 binding was determined for Abcc1, Abcc2, 
and Abcc4 (Fig.  4). No difference in Nrf2 binding was 
observed in a non-specific region of the same promoter 
(data not shown). These data show that Nrf2 can bind to 
the promoter of Abcc genes in brain microvessels under 
H/R conditions, providing evidence for molecular regula-
tion of drug efflux transporters (i.e., Mrps) at the BBB.
Discussion
The mammalian Mrp family belongs to the ABCC group 
of proteins, which contains 13 members including one 
ion channel (i.e., CFTR), two surface receptors (i.e., 
SUR1 and 2) and a truncated protein that does not medi-
ate transport (i.e., ABCC13) [2, 23]. Several functionally 
Fig. 1 Increased mRNA expression of Abcc1, Abcc2 and Abcc4 at 
the BBB following H/R. Female Sprague–Dawley rats were sub-
jected to H/R (Hx = 6% O2, 1 h; R = 21% O2 for 10 min, 30 min or 
1 h), normoxia (Nx), hypoxia (Hx), or administered the Nrf2 activator 
sulforaphane for 3 h. Results are expressed as mean ± SD of three 
experiments, with each group consisting of pooled microvessels from 
three individual animals. *p < 0.01
Fig. 2 H/R induces nuclear translocation of Nrf2 in rat brain microvessels. EMSA experiments (left-hand panel) show band shift to a higher molecu-
lar weight and an increase in band intensity in brain microvessels from female Sprague–Dawley rats subjected to H/R (H = 6% O2, 1 h; R = 21% O2 
for 10 min, 30 min or 1 h) and hypoxic (Hx) animals, as well as those treated with sulforaphane. The right-hand panel shows data from EMSA experi-
ments conducted in the presence of an excess (×200) of unlabeled probe. Image depicts a representative blot from three separate experiments
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characterized Mrp isoforms have been localized to the 
mammalian BBB. These include Mrp1, Mrp2, Mrp4, 
Mrp5 and Mrp6 [24–30]. The presence of multiple Mrp 
isoforms at the BBB is a critical determinant in control-
ling delivery of therapeutic agents to the brain. Addi-
tionally, the ability of Mrp isoforms to actively efflux the 
endogenous antioxidant glutathione (GSH) has signifi-
cant implications for diseases with an H/R component. 
GSH is responsible for maintenance of cellular redox 
balance and antioxidant defense in the brain. It has been 
previously demonstrated that various Mrps are upregu-
lated in response to oxidative stress conditions, which 
leads to enhanced cellular efflux of GSH [14]. Increased 
functional expression of Mrp isoforms at the BBB could 
cause reduced endothelial cell concentrations of GSH, an 
alteration in cellular redox status, and increased poten-
tial for cell injury and death. Therefore, biological mecha-
nisms that can modulate Mrp expression at the BBB in 
response to oxidative stress require further investigation.
A thorough understanding of signaling pathways 
involved in Mrp regulation in the setting of H/R will 
enable development of pharmacological approaches to 
target Mrp-mediated efflux (i.e., GSH transport) for the 
purpose of preventing BBB dysfunction. One intrigu-
ing pathway is signaling mediated by Nrf2, a sensor 
of oxidative stress [19, 31]. In the presence of ROS, the 
cytosolic Nrf2 repressor Keap1 undergoes structural 
alterations that cause dissociation from the Nrf2-Keap1 
complex. This enables Nrf2 to translocate to the nucleus 
and induce transcription of genes that possess an anti-
oxidant response element at their promoter [32, 33]. It 
has been demonstrated that activation of Nrf2 signaling 
induces expression of Mrp1, Mrp2, and Mrp4 [17–19, 
32, 34, 35]. Our data expands upon these previous stud-
ies by showing Nrf2-mediated increases in mRNA tran-
script expression for Abcc1, Abcc2, and Abcc4 in rat 
brain microvessels. We also show increased Nrf2 nuclear 
translocation in the setting of H/R and that Nrf2 binds 
to the ARE in the respective promoter for Abcc1, Abcc2, 
and Abcc4. Our findings are novel and highly significant 
because we have shown, for the first time, that H/R-
induced activation of Nrf2 leads to increased expres-
sion of mRNA transcripts for transporters endogenously 
expressed at the BBB. This is a rapid response, which may 
indicate that genes involved in the H/R stress response 
may be available for immediate activation in an effort 
to protect the vasculature from dysfunction and subse-
quent leak of circulating solutes. It is also intriguing that 
changes in Abcc mRNA transcript expression occur fol-
lowing H/R but are not apparent in the setting of hypoxia 
Fig. 3 H/R induces nuclear translocation of Nrf2 in rat brain 
microvessels. EMSA experiments using a specific Nrf2 monoclonal 
antibody (EP1808Y) show a “supershift” of bands corresponding to 
the nuclear Nrf2/ARE complex in brain microvessels from female 
Sprague–Dawley rats subjected to H/R (H = 6% O2, 1 h; R = 21% O2 
for 10 min, 30 min or 1 h) and hypoxic (Hx) animals, as well as those 
treated with sulforaphane. Image depicts a representative blot from 
three separate experiments
Fig. 4 Involvement of Nrf2 in regulation of Abcc mRNA transcripts 
in rat brain microvessels following H/R. ChIP was performed on 
brain microvessels isolated from rats subjected to H/R (H = 6% O2, 
1 h; R = 21% O2 for 10 min, 30 min or 1 h), Nx, Hx, or treated with 
sulforaphane for 3 h. Results are expressed as mean ± SD of three 
experiments, with each group consisting of pooled microvessels from 
three individual animals. *p < 0.05; **p < 0.01
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despite activation of Nrf2 signaling under both condi-
tions. Such changes may be reflective of the dramatic 
increase in ROS production following H/R. For example, 
Fabian and Kent demonstrated increased production of 
superoxide anions by neutrophils following reperfusion, 
an event that can greatly exacerbate BBB dysfunction [8, 
36]. Such dramatic increases in ROS production can cer-
tainly induce cellular changes independent of signaling 
pathways that are activated in response to hypoxia [37].
Recent evidence has shown that Nrf2 is a component 
of a complex signaling pathway, which involves additional 
factors for promoter activation and subsequent modula-
tion of transport mechanisms at the BBB. For example, 
sulforaphane-induced increases in ABC transporter 
functional expression at the BBB can be abolished using 
pifithrin, an inhibitor of p53 signaling, or in p53 null 
mice [19]. In contrast, nutlin-3, a p53 activator, increased 
P-gp transport activity in mouse brain capillaries [19]. 
Of particular note, this study also demonstrated that 
pharmacological inhibitors of p38 MAPK signaling (i.e., 
SB203580) and nuclear factor-κB (NF-κB) signaling (i.e., 
N4-[2-(4-phenoxyphenyl)ethyl]-4,6-quinazolinediamine, 
SN50) blocked effects of sulforaphane and nutlin-3 on 
P-gp activity [19]. Taken together, the work of Wang and 
colleagues suggests that effects of Nrf2 signaling on ABC 
transporters at the BBB requires involvement of p53, p38 
MAPK, and NF-κB signaling.
An emerging concept is that Nrf2 acts as a double-
edged sword [33]. Activation of Nrf2 signaling at the 
BBB is generally considered to be protective owing to 
its activation of cytoprotective pathways; pre- and post-
treatment administration of Nrf2 activators confer BBB 
protection in animal models of stroke and traumatic 
brain injury [38–40]. A subset of Nrf2 target genes are 
involved in the synthesis and metabolism of GSH, includ-
ing GCLC and GCLM (subunits of glutamate–cysteine 
ligase), glutathione peroxidase, and glutathione reduc-
tase [33]. Indeed, increased expression of GSH synthetic 
genes can lead to increased cellular production of this 
critical antioxidant. However, oxidative stress increases 
the functional expression of Mrp1 [14], and oxidative 
stress induced by metals or H2O2 has been previously 
shown to increase Mrp1-mediated export of GSH and 
GSSG [13, 41–43]. Upregulation of Mrp isoforms in glial 
cells may have neuroprotective effects in the setting of 
oxidative stress through release of GSH into brain paren-
chyma where it can be readily accessed by neurons [41, 
44]. However, an alteration in the balance of Mrp iso-
forms via activation of Nrf2 signaling may have consider-
ably different effects than in brain parenchyma. Indeed, 
efflux of GSH by Mrp isoforms expressed at the ablumi-
nal membrane of the BBB may provide some neuropro-
tection; however, increased GSH efflux due to enhanced 
Mrp-mediated transport can adversely affect redox bal-
ance and antioxidant defense at the brain microvascular 
endothelium and contribute to barrier dysfunction in 
the setting of H/R. This indicates that studies designed 
to develop pharmacological approaches based on target-
ing Mrp isoforms at the BBB must consider both neuro-
protective and vascular protective effects associated with 
these transporters. Additionally, increased functional 
expression of Mrp isoforms at the BBB can negatively 
affect endothelial cell inflammation and repair path-
ways. Endogenous mediators involved in such pathways 
include leukotriene C4, a known Mrp1/Mrp2 substrate 
[45, 46], and prostaglandin E2 [47].
In order to fully comprehend the implications of Nrf2-
mediated upregulation of Abcc gene expression at the 
BBB, future studies must be undertaken to assess Mrp 
localization in the brain microvasculature. Expression 
and localization of Mrp isoforms at the BBB is species-
dependent and remains highly controversial [48, 49]. 
Localization of Mrp1 is thought to be at the abluminal 
plasma membrane in brain microvascular endothelial 
cells in rodents, but at the luminal membrane in humans 
[50, 51]. Mrp4 has been detected on the luminal surface 
of the BBB in rat; however, abluminal expression has not 
been confirmed [50, 51]. Based on qPCR and proteomic 
analysis, Mrp4 is the most abundant of the three GSH-
transporting isoforms in human brain microvessels [29, 
50]. Mrp2 is likely localized to the luminal aspect of the 
BBB, but several studies have failed to detect Mrp2 at 
the protein level [49, 51]. This may be due to low basal 
expression of Mrp2, which may be increased in response 
to cellular stressors such as oxidative stress [28, 52]. 
In mice, there are notable differences in Mrp expres-
sion between strains and between vessels of different 
diameters. For example, FVB mice appear to lack Mrp2 
in brain vessels, but it is present in C57BL/6 and Swiss 
mice [53]. This same study also showed that Mrp1is most 
abundant in vessels 20–50 μm in diameter [53]. Rigorous 
assessment of Mrp isoform localization will undoubt-
edly inform the development of therapeutic strategies 
to protect the BBB in diseases with an H/R component. 
Furthermore, these studies should include both male and 
female experimental animals in order to determine differ-
ences in Mrp localization based on sex.
Conclusion
Our data show increased Abcc1, Abcc2, and Abcc4 mRNA 
expression at the BBB in response to H/R stress and 
that Abcc gene expression is regulated by Nrf2 signaling 
(Fig. 5). This is the first time that Nrf2 signaling has been 
shown to modulate Abcc genes at the brain microvas-
culature in the setting of H/R stress. Since Mrp1, Mrp2, 
and Mrp4 transport GSH, these results have considerable 
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pharmacological implications as they point to endog-
enous transporters that can be targeted for development 
of novel therapeutic strategies to confer BBB protection. 
Furthermore, our in vivo H/R treatment does not induce 
necrotic damage to the endothelium, thus enabling us to 
study a dynamically regulated and recoverable BBB. Such 
a model can inform novel strategies to target the penum-
bra in ischemic stroke, which is subject to hypoxic insult 
but can be potentially rescued using pharmacological 
interventions. Future studies are ongoing in our labora-
tory to examine functional implications of Nrf2-medi-
ated increases in Abcc transcript expression, particularly 
with respect to Mrp protein expression and brain-to-
blood transport of GSH, in order to rigorously examine 
the utility of Mrp isoforms as a therapeutic target in dis-
eases with an H/R component.
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